Loading...
Royalty Pharma plc
RPRX•NASDAQ
HealthcareBiotechnology
$33.78
$0.03(0.09%)
Royalty Pharma plc (RPRX) Financial Performance & Statements
Review Royalty Pharma plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-3.85%
↓ 3.85%
Operating Income Growth
-13.41%
↓ 13.41%
Net Income Growth
-24.31%
↓ 24.31%
Operating Cash Flow Growth
-7.32%
↓ 7.32%
Operating Margin
83.95%
↑ 83.95%
Gross Margin
99.66%
↑ 99.66%
Net Profit Margin
48.24%
↑ 48.24%
ROE
16.19%
↑ 16.19%
ROIC
11.57%
↑ 11.57%
Royalty Pharma plc (RPRX) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Royalty Pharma plc stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $594.00M | $564.69M | $537.27M | $567.98M |
| Cost of Revenue | $0.00 | $1.65M | $6.00M | $583.60M |
| Gross Profit | $594.00M | $563.04M | $531.27M | -$15.62M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.99 | -$0.03 |
| R&D Expenses | $1.00M | $500000.00 | $500000.00 | $500000.00 |
| SG&A Expenses | $68.00M | $56.72M | $54.71M | $57.65M |
| Operating Expenses | $232.00M | -$170.38M | $267.64M | $641.75M |
| Total Costs & Expenses | $232.00M | -$170.38M | $267.64M | $641.75M |
| Interest Income | $0.00 | $17.51M | $13.38M | $7.42M |
| Interest Expense | $66.00M | $66.51M | $49.01M | $44.23M |
| Depreciation & Amortization | $0.00 | $137.79M | $560.00M | $729.77M |
| EBITDA | $362.00M | $872.86M | $560.00M | $39.96M |
| EBITDA Ratio | $0.61 | $1.55 | $1.04 | $0.07 |
| Operating Income | $362.00M | $735.07M | $269.63M | -$73.77M |
| Operating Income Ratio | $0.61 | $1.30 | $0.50 | -$0.13 |
| Other Income/Expenses (Net) | -$28.00M | $71.28M | -$75.25M | $69.50M |
| Income Before Tax | $334.00M | $806.36M | $194.38M | -$4.27M |
| Income Before Tax Ratio | $0.56 | $1.43 | $0.36 | -$0.008 |
| Income Tax Expense | $126.00M | $0.00 | $92.37M | -$9.05M |
| Net Income | $208.00M | $543.99M | $102.004M | $4.78M |
| Net Income Ratio | $0.35 | $0.96 | $0.19 | $0.008 |
| EPS | $0.46 | $1.61 | $0.23 | $0.01 |
| Diluted EPS | $0.35 | $1.21 | $0.23 | $0.01 |
| Weighted Avg Shares Outstanding | $447.63M | $447.63M | $451.02M | $448.62M |
| Weighted Avg Shares Outstanding (Diluted) | $592.73M | $592.73M | $596.91M | $597.48M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan